Assessment of CYP450 genetic variability effect on methadone dose and tolerance-Reference-Cited by-全球学者库

Assessment of CYP450 genetic variability effect on methadone dose and tolerance

Published:2014-05 Issue:7 Volume:15 Page:977-986
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Tsai Hui-Ju¹²³,Wang Sheng-Chang⁴,Liu Sheng-Wen⁴,Ho Ing-Kang⁴⁵⁶,Chang Yao-Sheng⁴,Tsai Yu-Ting¹,Lin Keh-Ming⁴,Liu Yu-Li⁴⁷

Affiliation:

1. Division of Biostatistics & Bioinformatics, Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Miaoli County, Taiwan

2. Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

3. Department of Genome Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

4. Center for Neuropsychiatric Research, National Health Research Institutes, Zhunan, Miaoli County, Taiwan

5. Center for Drug Abuse & Addiction, China Medical University Hospital, Taiwan

6. Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan

7. Department of Psychiatry, National Taiwan University Hospital & National Taiwan University College of Medicine, Taipei, Taiwan

Abstract

Aim: Methadone dose is related to treatment success in individuals under methadone maintenance treatment (MMT). We constructed a gene matrix using previously identified genetic polymorphisms in CYP450 and determined their genetic influence on methadone dose or tolerance. Materials & methods: The allelic combinations of CYP450 genetic variants (two from CYP2C19, four from CYP2B6 and five from CYP3A4) were analyzed in 366 MMT heroin dependent patients as possible determinants of methadone dose and tolerance using analysis of covariance. Results: Methadone dose (p = 0.007) and tolerance (p = 0.06) were mainly influenced by CYP2C19 gene dose. Moreover, dominant influence of the CYP2C19 gene dose on methadone dose and tolerance was only found among MMT patients with negative urine morphine test results, but not among those with positive results. Conclusion: The findings suggest that CYP2C19 gene dose may serve as a potential indicator for assessing methadone dose and tolerance in MMT patients. Original submitted 5 September 2013; Revision submitted 23 January 2014

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs.14.19

Reference36 articles.

1. Pharmacogenetics of alcohol, nicotine and drug addiction treatments

2. Buprenorphine Replacement Therapy for Adolescents with Opioid Dependence: Early Experience from a Children’s Hospital-Based Outpatient Treatment Program

3. Opioid Dependence Treatment and Guidelines

4. Methadone in Hair and Sweat From Patients in Long-Term Maintenance Therapy

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of the D-amino acid oxidase gene with methadone dose in heroin dependent patients under methadone maintenance treatment;Journal of Human Genetics;2022-01-04

2. New method of creating hybrid of buprenorphine loaded rifampin/polyethylene glycol/alginate nanoparticles;International Journal of Biological Macromolecules;2020-09

3. Genetic variants in NECTIN4 encoding an adhesion molecule are associated with continued opioid use;PLOS ONE;2020-06-18

4. Precision therapeutic opioid dosing implications from genetic biomarkers and craving score;Medicine;2020-05-29

5. New and Enzymatic Targeted Magnetic Macromolecular Nanodrug System Which Delivers Methadone and Rifampin Simultaneously;ACS Biomaterials Science & Engineering;2019-12-18